These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38102446)

  • 1. Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
    Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S
    Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
    Voutilainen S; Heikkilä P; Bartkova J; Nevanlinna H; Blomqvist C; Bartek J; Mattson J
    BMC Cancer; 2022 Dec; 22(1):1298. PubMed ID: 36503417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
    Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
    Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
    Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
    Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune parameters associated with survival in metaplastic breast cancer.
    Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
    Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.
    Brcic I; Kluba AM; Godschachner TM; Suppan C; Regitnig P; Dandachi N; Lax SF; Balić M
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
    Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression and tumor-infiltrating lymphocytes: Correlations and prognostic values in Chinese triple-negative breast cancer patients with different molecular subtyping.
    Li Y; Ma J; Ma X; Chen C; Ruan M; Yang W; Shui R
    Pathol Res Pract; 2024 Oct; 262():155556. PubMed ID: 39216323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
    Kalaw E; Lim M; Kutasovic JR; Sokolova A; Taege L; Johnstone K; Bennett J; Saunus JM; Niland C; Ferguson K; Gresshoff I; Bettington M; Pathmanathan N; Tse GM; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox S; O'Toole SA; Simpson PT; Lakhani SR; McCart Reed AE
    Br J Cancer; 2020 Nov; 123(11):1665-1672. PubMed ID: 32939056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.
    Chartier S; Brochard C; Martinat C; Coussy F; Feron JG; Kirova Y; Cottu P; Marchiò C; Vincent-Salomon A
    Histopathology; 2023 Apr; 82(5):664-671. PubMed ID: 36527253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
    Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
    BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tumor-infiltrating lymphocytes, PD-L1, and
    Reznitsky FM; Jensen JD; Knoop A; Jensen MB; Laenkholm AV
    Acta Oncol; 2023 Dec; 62(12):1913-1920. PubMed ID: 37961947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
    Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
    Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.